Remove 2004 Remove Dosage Remove Vaccines
article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. December 21, 2004. PR Newswire. June 10, 2025. Accessed June 10, 2025.

FDA 73
article thumbnail

Navigating delivery challenges of nucleic acid therapeutics

European Pharmaceutical Review

According to the authors, self-amplifying RNA (saRNA) could be a next-generation vaccine platform, but it requires smart drug delivery vehicles to maintain the long-term stability and efficiency of the drug. The current NA dosage forms and novel DDSs have enabled the successful launch of NA therapeutics globally. Ingle et al.

Dosage 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

Market Cap: $8.46M Founded Year: 2004 Total Employees: ~4 Headquarters: Texas, United States Stock Exchange: OTCMKTS QSam Biosciences is a clinical-stage biotech company focused on developing and commercializing targeted therapeutic radiopharmaceutical products for treating cancer and related diseases.

FDA 56
article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. 6 US Food and Drug Administration. Burke, S., Hammond, and T.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

POD is suitable for a wide range of products, including oral solid dosage forms, mAbs, and cell therapy. September 2004. Duplication enables rapid scale-up and scale-out, new facilities can be constructed in less than 12 months, and isolated operation avoids cross-contamination. Journal of Pharmaceutical Sciences 111, no.